Library
PubMed
research article
Professional

Sarcopenia predicts the recompensation in patients with decompensated cirrhosis.

Source: PubMed, NCBI / U.S. National Library of Medicine

Clinical and translational gastroenterologyWei Ning, Liu Minghui, Gu Li, et al.Published 6/9/2026Last synced 6/10/2026Status: syncedPMID: 42263220DOI: 10.14309/ctg.0000000000001050

Sarcopenia is associated with increased mortality and poor clinical outcomes in patients with liver cirrhosis. However, the correlation between sarcopenia and recompensation has not been determined until now. In this study, we aimed to evaluate the performance of sarcopenia in predicting recompensation in patients with decompensated cirrhosis. A total of 258 patients with decompensated cirrhosis were enrolled in this retrospective study, and the data of enrolled patients were collected and analyzed. 36.82% of patients with decompensated cirrhosis achieved recompensation. The etiology of liver cirrhosis in these patients included HBV, HCV, alcoholic liver disease, autoimmune liver diseases, schistosomiasis infection, and nonalcoholic fatty liver disease. The decompensating events in these patients included ascites (43.02%), esophagogastric variceal bleeding (42.25%), hepatic encephalopathy (5.23%), etc. 27.06% of decompensated patients with sarcopenia and 41.62% of patients without sarcopenia achieved recompensation. Univariate logistic analysis demonstrated several variables were associated with recompensation, including erythrocyte, hemoglobin, L3 skeletal muscle index (SMI), sarcopenia and subcutaneous fat area (SFA) (all p<0.05). Multivariate analysis demonstrated sarcopenia (OR=0.52; p=0.03) and hemoglobin (OR=1.02; p<0.01) were independent predictors for recompensation. Sarcopenia and hemoglobin were independent predictors for recompensation of decompensated patients, wh

Abstract

Sarcopenia is associated with increased mortality and poor clinical outcomes in patients with liver cirrhosis. However, the correlation between sarcopenia and recompensation has not been determined until now. In this study, we aimed to evaluate the performance of sarcopenia in predicting recompensation in patients with decompensated cirrhosis. A total of 258 patients with decompensated cirrhosis were enrolled in this retrospective study, and the data of enrolled patients were collected and analyzed. 36.82% of patients with decompensated cirrhosis achieved recompensation. The etiology of liver cirrhosis in these patients included HBV, HCV, alcoholic liver disease, autoimmune liver diseases, schistosomiasis infection, and nonalcoholic fatty liver disease. The decompensating events in these patients included ascites (43.02%), esophagogastric variceal bleeding (42.25%), hepatic encephalopathy (5.23%), etc. 27.06% of decompensated patients with sarcopenia and 41.62% of patients without sarcopenia achieved recompensation. Univariate logistic analysis demonstrated several variables were associated with recompensation, including erythrocyte, hemoglobin, L3 skeletal muscle index (SMI), sarcopenia and subcutaneous fat area (SFA) (all p<0.05). Multivariate analysis demonstrated sarcopenia (OR=0.52; p=0.03) and hemoglobin (OR=1.02; p<0.01) were independent predictors for recompensation. Sarcopenia and hemoglobin were independent predictors for recompensation of decompensated patients, which helped to identify high-risk patients who have difficulty in achieving recompensation.

Educational only
This information is for general education and is not medical advice. Always talk to a licensed U.S. clinician about your situation, medications, or treatment decisions.